AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
NEW YORK, March 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp. (“CTI BioPharma”) (NASDAQ:CTIC) pursuant or traceable to the Registration Statement and Prospectus issued in connection with the September 24, 2015 Public Offering and/or between March 4, 2014 and February 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/cti-biopharma.
The complaint alleges that the documents filed in connection with the offering contained materially false and misleading statements and/or omissions, including: (1) the detrimental effect on survival of experimental treatment pacritinib; (2) that the Company’s clinical trials demonstrated deaths associated with pacritinib usage; (3) that the Company’s new drug application for pacritinib would likely be withdrawn; (4) that, as such, the Company’s future revenues were impaired; and (5) that the company lacked adequate internal controls.
On February 8, 2016, it was revealed that the FDA had placed a partial hold on clinical studies of pacritinib, citing “identified…fatal and life-threatening safety issues in pacritinib-treated patients…”
If you suffered a loss in CTI BioPharma you have until April 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cti-biopharma.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
